Summary
Cencora, Inc. (COR), formerly AmerisourceBergen, reported solid revenue growth for the quarter ended December 31, 2022, with a 5.4% increase year-over-year, driven primarily by its U.S. Healthcare Solutions segment. This growth was fueled by increased unit volumes and expanded sales to specialty physician practices, though partially offset by declining sales of COVID-19 treatments. The company also demonstrated improved gross profit, up 4.2%, benefiting from higher gross profit in its U.S. operations and a one-time gain from antitrust litigation settlements. While operating expenses rose due to increased distribution, selling, and administrative costs, the company managed to control litigation and opioid-related expenses. Despite a slight decrease in total segment operating income, largely due to international currency headwinds, Cencora's financial performance indicates resilience and continued operational execution.
Financial Highlights
55 data points| Revenue | $62.85B |
| Cost of Revenue | $60.70B |
| Gross Profit | $2.15B |
| SG&A Expenses | $1.29B |
| Operating Income | $633.14M |
| Net Income | $479.75M |
| EPS (Basic) | $2.35 |
| EPS (Diluted) | $2.33 |
| Shares Outstanding (Basic) | 204.03M |
| Shares Outstanding (Diluted) | 206.33M |
Key Highlights
- 1Revenue increased by 5.4% to $62.8 billion compared to the prior year quarter, primarily driven by the U.S. Healthcare Solutions segment's 6.1% growth.
- 2Gross profit rose by 4.2% to $2.1 billion, supported by increased sales in the U.S. and a $49.9 million gain from antitrust litigation settlements.
- 3Operating income for U.S. Healthcare Solutions saw a modest 0.6% increase, reaching $572.4 million, while International Healthcare Solutions operating income decreased by 10.4% to $161.3 million.
- 4The company repurchased $778.8 million of its common stock during the quarter, demonstrating a commitment to returning capital to shareholders.
- 5Effective tax rate decreased to 19.8% from 24.6% in the prior year quarter, positively impacting net income.
- 6Significant event post-quarter: Cencora announced its intent to change its name from AmerisourceBergen, effective in the second half of 2023, signaling a strategic shift.
- 7The company completed the acquisition of PharmaLex Holding Gmbh for €1.381 billion effective January 1, 2023, expanding its international services for the life sciences industry.